Cardiovascular Risk Reduction with Ezetimibe and Pravastatin

Lipid-Lowering Effects

The American Heart Association recommends that patients with high cardiovascular risk receive combination therapy with ezetimibe and pravastatin, which achieves LDL-C reductions of approximately 42% from untreated baseline, with maximal lipid-lowering effects achieved by 4-6 weeks 1
Liver enzyme monitoring, such as ALT, should occur at baseline and during early treatment with pravastatin, as it can cause transaminase elevations in approximately 1.1% of patients 1

The American College of Cardiology recommends that patients with established coronary heart disease receive long-term therapy with pravastatin 40mg, which reduces major coronary events by approximately 27% after 2+ years 1
In secondary prevention populations with diabetes, pravastatin 40mg produces an absolute risk reduction of 8% for cardiovascular events over approximately 5 years 2, 3
The addition of ezetimibe to statin therapy produces a 2% absolute reduction in cardiovascular death, major coronary events, or stroke after 7 years of treatment 4, 5

The combination of ezetimibe and pravastatin is generally well tolerated, with a safety profile similar to pravastatin monotherapy, and no cases of severe myopathy (rhabdomyolysis) were observed with pravastatin 40mg in major trials 1, 6

The American College of Cardiology recommends measurement of lipid profiles to document baseline and assess response to therapy, but timing matters 7
Pravastatin 40mg monotherapy produces approximately 30-35% LDL-C reduction, according to the American College of Cardiology 7

The American College of Cardiology recommends repeat lipid panel at 4-6 weeks to assess true therapeutic response, as maximal lipid-lowering effects are achieved by this time 7
Individual responses to statin therapy vary significantly in clinical practice, even though population-level estimates are reliable, as noted by the American College of Cardiology 7